Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Emilia Quattrocchi; Mikkel Ostergaard; Peter C. Taylor; Ronald F. van Vollenhoven; Myron Chu; Stephen Mallett; Hayley Perry; Regina Kurrasch

doi:10.1371/journal.pone.0157961

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Emilia Quattrocchi, Mikkel Ostergaard, Peter C. Taylor, Ronald F. van Vollenhoven, Myron Chu, Stephen Mallett, Hayley Perry, Regina Kurrasch

Department of Clinical Medicine

10 Citations (Scopus)

49 Downloads (Pure)

Original language	English
Article number	e0157961
Journal	PLOS ONE
Volume	11
Issue number	6
Number of pages	19
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0157961
Publication status	Published - 23 Jun 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0157961Licence: CC BY

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical TrialsFinal published version, 1.15 MBLicence: CC BY

Cite this

Quattrocchi, E., Ostergaard, M., Taylor, P. C., van Vollenhoven, R. F., Chu, M., Mallett, S., Perry, H., & Kurrasch, R. (2016). Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials. PLOS ONE, 11(6), [e0157961]. https://doi.org/10.1371/journal.pone.0157961

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis : Results from Three Clinical Trials. / Quattrocchi, Emilia; Ostergaard, Mikkel; Taylor, Peter C. et al.

In: PLOS ONE, Vol. 11, No. 6, e0157961, 23.06.2016.

Research output: Contribution to journal › Journal article › Research › peer-review

Quattrocchi, E, Ostergaard, M, Taylor, PC, van Vollenhoven, RF, Chu, M, Mallett, S, Perry, H & Kurrasch, R 2016, 'Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials', PLOS ONE, vol. 11, no. 6, e0157961. https://doi.org/10.1371/journal.pone.0157961

@article{5199d0e52d8040ad8a62e457c09d9873,

title = "Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials",

author = "Emilia Quattrocchi and Mikkel Ostergaard and Taylor, {Peter C.} and {van Vollenhoven}, {Ronald F.} and Myron Chu and Stephen Mallett and Hayley Perry and Regina Kurrasch",

year = "2016",

month = jun,

day = "23",

doi = "10.1371/journal.pone.0157961",

language = "English",

volume = "11",

journal = "PLoS Computational Biology",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "6",

}

TY - JOUR

T1 - Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis

T2 - Results from Three Clinical Trials

AU - Quattrocchi, Emilia

AU - Ostergaard, Mikkel

AU - Taylor, Peter C.

AU - van Vollenhoven, Ronald F.

AU - Chu, Myron

AU - Mallett, Stephen

AU - Perry, Hayley

AU - Kurrasch, Regina

PY - 2016/6/23

Y1 - 2016/6/23

U2 - 10.1371/journal.pone.0157961

DO - 10.1371/journal.pone.0157961

M3 - Journal article

C2 - 27336685

SN - 1932-6203

VL - 11

JO - PLoS Computational Biology

JF - PLoS Computational Biology

IS - 6

M1 - e0157961

ER -

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

UN SDGs

Access to Document

Fingerprint

Cite this